In November 2020, the new intra-DRG was published on the website of the French Ministry of Solidarity and Health. A new chapter was added for urogenital implants - “Implantable devices for the treatment of female stress urinary incontinence.”
In France, certain medical devices are financed within the DRG tariff but require an explicit review of clinical evidence by CNEDiMTS to ensure that they are safe and effective. This mechanism is called “within-DRG (intra-GHS) coverage.” The mechanism is applicable to particularly invasive devices. Only devices listed in the intra-GHS list can be purchased by hospitals. After the positive evaluation by the National Authority for Health (HAS), the devices are included in the intra-DRG list maintained by the Ministry of Solidarity and Health.
In November 2020, the new intra-DRG list was published. The chapter “Implantable devices for the treatment of female stress urinary incontinence” was introduced under the title II “Urogenital implants.” Twelve suburethral bands implanted by retropubic and/or transobturator approach are listed under this chapter.
The full details in French can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).